Sab Biotherapeutics Inc (SABS) Stock Price, Quote & News

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Flo...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 845 2813

Website: www.sab.bio

Address:

777 W 41st St., Miami Beach, United States

BioRich Jun. 16 at 4:42 AM

$SABS As this has all the feels of breaking out, I decided to look at the management team. Strong. In particular, I like a Chief Medical Officer with the experience and Big Pharma ties that $SABS's CMO has. $TEVA $SNY $PFE $IBIO . Looks good to me. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply

DDiamond_Handz Jun. 15 at 9:39 PM

$SABS

0 · Reply

topstockalerts Jun. 15 at 8:40 PM

$SABS didn’t expect this much follow-through

0 · Reply

BioRich Jun. 15 at 3:37 PM

$MRK You bought $VRNA (thank you very much) so why not just work with Mr. Z to get a deal done for $SABS? That would be great appeciated as well. Cheers!

0 · Reply

BioRich Jun. 15 at 3:35 PM

$SAB Thanks to @Trainguy1 for making this massive connection between $SABS's new/current Chairman of the Board (BoD) and $VRNA. Looks like Mr. Zaccardelli has a knack for productively progressing clinical drugs to approval, and then getting bought out. $SABS is one of the most under the radar, under valued stocks out there. I think we stumbled upon a winner. Thanks for the connection @Trainguy1 Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI

0 · Reply

BioRich Jun. 15 at 2:09 PM

$SABS Great way to start the day with $SABS. Sleeping giant here. They always seem to impress with their presentations and excitement surrounding their discoveries so I see them getting the right attention sooner than later. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply

Dubbyy Jun. 15 at 2:04 PM

$SABS Check out this article from TipRanks | SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained | https://tipranks.onelink.me/WJho/9pk7rc2y

0 · Reply

Dubbyy Jun. 15 at 1:52 PM

$SABS

0 · Reply

Trainguy1 Jun. 15 at 1:50 PM

$SABS David Zaccardelli is at it again. He brought Verona from about $5/sh to over $100/sh. Can he repeat that feat with SABS? I hope so!

1 · Reply

high_tech_texan Jun. 15 at 1:46 PM

$SABS 15 minutes in, and we've already surpassed the average daily volume - nicw!

0 · Reply

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

2026-05-22T09:15:45.000Z - 24 days ago

SAB Biotherapeutics initiated with a Buy at Citi

2026-05-20T09:05:51.000Z - 26 days ago

SAB Biotherapeutics initiated with a Buy at Jefferies

May 13, 2026, 7:00 AM EDT - 4 weeks ago

SAB Biotherapeutics Slides: Corporate presentation

2026-05-12T18:00:35.000Z - 4 weeks ago

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

May 12, 2026, 8:30 AM EDT - 4 weeks ago

SAB Biotherapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 8:30 AM EDT - 4 weeks ago

SAB Biotherapeutics Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 4 weeks ago

SAB Biotherapeutics Quarterly report: Q1 2026

May 12, 2026, 7:30 AM EDT - 4 weeks ago

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

May 5, 2026, 8:30 AM EDT - 5 weeks ago

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Apr 30, 2026, 8:00 AM EDT - 6 weeks ago

SAB Biotherapeutics Proxy statement: Proxy filing

2026-04-29T12:30:52.000Z - 6 weeks ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

EBS

Apr 22, 2026, 7:00 AM EDT - 7 weeks ago

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

2026-04-02T11:26:22.000Z - 2 months ago

SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

Mar 19, 2026, 4:01 PM EDT - 3 months ago

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-18T10:12:35.000Z - 3 months ago

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

Mar 17, 2026, 10:46 PM EDT - 3 months ago

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

2026-03-17T21:35:16.000Z - 3 months ago

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

2026-03-17T20:05:50.000Z - 3 months ago

SAB Biotherapeutics announces common stock offering, no amount given

Mar 17, 2026, 4:01 PM EDT - 3 months ago

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-03-10T23:25:30.000Z - 3 months ago

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

2026-03-10T11:41:43.000Z - 3 months ago

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

Mar 10, 2026, 7:31 AM EDT - 3 months ago

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

Mar 9, 2026, 5:16 PM EDT - 3 months ago

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 3:00 PM EDT - 3 months ago

SAB Biotherapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 7:00 AM EDT - 3 months ago

SAB Biotherapeutics Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 3 months ago

SAB Biotherapeutics Annual report: Q4 2025

Mar 2, 2026, 9:00 AM EST - 3 months ago

SAB BIO to Participate in Upcoming Investor Conferences

Feb 25, 2026, 8:40 AM EST - 3 months ago

SAB Biotherapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026, 10:30 AM EST - 4 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 15, 2026, 10:30 AM EST - 5 months ago

SAB Biotherapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 months ago

SAB Biotherapeutics Slides: Corporate presentation

2026-01-07T13:27:50.000Z - 5 months ago

SAB Biotherapeutics initiated with a Buy at UBS

2026-01-07T13:12:17.000Z - 5 months ago

SAB Biotherapeutics appoints David Zaccardelli as board chair

Jan 7, 2026, 8:00 AM EST - 5 months ago

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Jan 6, 2026, 8:00 AM EST - 5 months ago

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-30T15:15:19.000Z - 5 months ago

SAB Biotherapeutics files $300M mixed securities shelf

Dec 29, 2025, 7:00 AM EST - 6 months ago

SAB Biotherapeutics Registration statement: Registration Filing

2025-12-19T11:36:31.000Z - 6 months ago

SAB Biotherapeutics initiated with a Buy at Guggenheim

2025-12-18T13:05:56.000Z - 6 months ago

SAB Biotherapeutics announces first patient dosed in SAFEGUARD trial

Dec 18, 2025, 8:00 AM EST - 6 months ago

First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

2025-12-17T13:12:49.000Z - 6 months ago

SAB Biotherapeutics Phase 1 trial of SAB-142 met primary endpoint

Dec 17, 2025, 8:00 AM EST - 6 months ago

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

2025-12-08T13:26:26.000Z - 6 months ago

SAB Biotherapeutics to present data on progress in development of SAB-142

Dec 8, 2025, 8:00 AM EST - 6 months ago

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Dec 2, 2025, 3:50 PM EST - 6 months ago

SAB Biotherapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 14, 2025, 4:00 PM EST - 7 months ago

SAB Biotherapeutics Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 7 months ago

SAB Biotherapeutics Quarterly report: Q3 2025

Nov 13, 2025, 5:00 PM EST - 7 months ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov 12, 2025, 10:00 AM EST - 7 months ago

SAB Biotherapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 2:45 PM EST - 7 months ago

SAB Biotherapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Sep 22, 2025, 8:00 AM EDT - 9 months ago

SAB Biotherapeutics Registration statement: Registration Filing

Sep 19, 2025, 7:24 AM EDT - 9 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

Sep 3, 2025, 4:05 PM EDT - 10 months ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Sep 2, 2025, 8:00 AM EDT - 10 months ago

SAB Biotherapeutics Registration statement: Registration Filing

Aug 29, 2025, 8:00 AM EDT - 10 months ago

SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 19, 2025, 8:00 AM EDT - 10 months ago

SAB Biotherapeutics Proxy statement: Proxy Filing

Aug 7, 2025, 7:30 AM EDT - 11 months ago

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

Aug 7, 2025, 7:00 AM EDT - 11 months ago

SAB Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 11 months ago

SAB Biotherapeutics Quarterly report: Q2 2025

Jul 21, 2025, 7:30 AM EDT - 11 months ago

SAB BIO Announces Oversubscribed $175 Million Private Placement

Jun 2, 2025, 8:00 AM EDT - 1 year ago

SAB Biotherapeutics Proxy statement: Proxy Filing

May 9, 2025, 9:00 AM EDT - 1 year ago

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q1 2025

May 8, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Quarterly report: Q1 2025

Mar 31, 2025, 7:32 AM EDT - 1 year ago

SAB BIO Reports Full Year 2024 Operating and Financial Results

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Earnings release: Q4 2024

Mar 30, 2025, 6:00 PM EDT - 1 year ago

SAB Biotherapeutics Annual report: Q4 2024

Feb 12, 2025, 10:00 AM EST - 1 year ago

SAB Biotherapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 6, 2025, 2:00 PM EST - 1 year ago

SAB Biotherapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 28, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Jan 23, 2025, 7:00 AM EST - 1 year ago

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Nov 19, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Slides: Corporate Presentation

Nov 6, 2024, 5:05 PM EST - 1 year ago

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

SAB Biotherapeutics Earnings release: Q3 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

Sep 9, 2024, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Press release: Study Update

Sep 9, 2024, 7:00 AM EDT - 1 year ago

SAB Biotherapeutics Slides: Study Update

Sep 4, 2024, 7:05 AM EDT - 1 year ago

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Aug 8, 2024, 5:51 PM EDT - 2 years ago

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

Aug 8, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Quarterly report: Q2 2024

Aug 5, 2024, 7:30 AM EDT - 2 years ago

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

Jul 31, 2024, 7:30 AM EDT - 2 years ago

SAB BIO Appoints Lucy To as Chief Financial Officer

Jun 20, 2024, 7:20 AM EDT - 2 years ago

SAb Biotherapeutics Rebrands as SAB BIO

Jun 18, 2024, 1:10 PM EDT - 2 years ago

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

May 30, 2024, 4:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 30, 2024, 8:00 AM EDT - 2 years ago

SAB Biotherapeutics Proxy statement: Proxy Filing

May 21, 2024, 7:15 AM EDT - 2 years ago

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

May 20, 2024, 5:45 PM EDT - 2 years ago

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Earnings release: Q1 2024

May 20, 2024, 7:00 AM EDT - 2 years ago

SAB Biotherapeutics Quarterly report: Q1 2024

May 6, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

Apr 16, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics Provides SAB-142 Trial Update

Apr 8, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at INNODIA Annual Meeting

Apr 4, 2024, 7:15 AM EDT - 2 years ago

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

BioRich Jun. 16 at 4:42 AM

0 · Reply

DDiamond_Handz Jun. 15 at 9:39 PM

$SABS

0 · Reply

topstockalerts Jun. 15 at 8:40 PM

$SABS didn’t expect this much follow-through

0 · Reply

BioRich Jun. 15 at 3:37 PM

$MRK You bought $VRNA (thank you very much) so why not just work with Mr. Z to get a deal done for $SABS? That would be great appeciated as well. Cheers!

0 · Reply

BioRich Jun. 15 at 3:35 PM

0 · Reply

BioRich Jun. 15 at 2:09 PM

0 · Reply

Dubbyy Jun. 15 at 2:04 PM

$SABS Check out this article from TipRanks | SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained | https://tipranks.onelink.me/WJho/9pk7rc2y

0 · Reply

Dubbyy Jun. 15 at 1:52 PM

$SABS

0 · Reply

Trainguy1 Jun. 15 at 1:50 PM

$SABS David Zaccardelli is at it again. He brought Verona from about $5/sh to over $100/sh. Can he repeat that feat with SABS? I hope so!

1 · Reply

high_tech_texan Jun. 15 at 1:46 PM

$SABS 15 minutes in, and we've already surpassed the average daily volume - nicw!

0 · Reply

JMSF Jun. 15 at 1:45 PM

$SABS

0 · Reply

DARKP00L Jun. 15 at 1:21 PM

$SABS 08:59 on Jun. 15 2026 Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12 #tradeideas

0 · Reply

JuggernautRaider Jun. 14 at 11:43 AM

Brother @Rungreen , you know i’m all about $TNXP , $SLS …. And $CADL is quite intriguing But isn’t $SABS in the type 1 diabetes space? Remember LXRX? If they’re not bought soon… how can they compete in America? 🇺🇸 🧐 🚀

1 · Reply

stockboyaisle1 Jun. 13 at 12:10 PM

$SABS

1 · Reply

Doom_Gloom_AR Jun. 12 at 6:43 AM

$SABS stock chart is ugly stepped out of this over $4.X on the hanta pump. will be back,I stalk my victims prior to the kill. might have a strong buy opp at good prices soon.

0 · Reply

JTebow_CWS Jun. 12 at 2:50 AM

$SABS https://www.statnews.com/sponsor/2026/06/01/going-beyond-insulin-in-type-1-diabetes-a-new-wave-of-disease-modifying-therapies/

1 · Reply

RAClose Jun. 11 at 5:47 AM

$SABS Once a $131 stock.... maybe congress didn't get the message to activate their insider trading on this one....

3 · Reply

stockboyaisle1 Jun. 4 at 7:19 PM

$SABS

0 · Reply

DDiamond_Handz Jun. 3 at 1:37 PM

$SABS is the broader market holding this back or was all the good news just priced in already?

3 · Reply

Cinderblocks Jun. 1 at 7:43 PM

$SABS Keeps getting pummeled despite all the good news. Oh well. I guess I got to wait.

1 · Reply

JTebow_CWS May. 30 at 2:36 AM

$SABS

0 · Reply

Ruff22 May. 29 at 12:16 PM

$SABS ACA 2026 - June 5-8 https://www.webullapp.com/news-detail/14965100233958400?theme=1&hl=en&color=2&_v=1&tickerId=925241098&disSymbol=SABS&sourcePage=Stock_NewsList&sp=0&hl=en

1 · Reply

Market Cap	254.63M
Revenue (ttm)	0.00
Net Income (ttm)	13.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	5,976,900
Avg Vol	643,022
Day's Range	N/A - N/A
Shares Out	76.46M
Stochastic %K	19%
Beta	0.54
Analysts	Strong Sell
Price Target	$10.30